A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers

A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers

Conditions: Endometrial Neoplasms; Ovarian Neoplasms; Soft Tissue Sarcoma (STS); Glioblastoma
Interventions: Drug: AL58805; Drug: AL3818; Drug: Temozolomide (TMZ); Drug: CCNU
Sponsors: Advenchen Pharmaceuticals, LLC.
Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 11, 2026Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments